- Home
- JNPR vs EXEL Comparison
JNPR vs EXEL Comparison
Compare JNPR & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JNPR
- EXEL
- Stock Information
- Founded
- JNPR 1996
- EXEL 1994
- Country
- JNPR United States
- EXEL United States
- Employees
- JNPR N/A
- EXEL N/A
- Industry
- JNPR Computer Communications Equipment
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JNPR Telecommunications
- EXEL Health Care
- Exchange
- JNPR Nasdaq
- EXEL Nasdaq
- Market Cap
- JNPR 11.9B
- EXEL 9.4B
- IPO Year
- JNPR 1999
- EXEL 2000
- Fundamental
- Price
- JNPR $35.61
- EXEL $37.09
- Analyst Decision
- JNPR Buy
- EXEL Buy
- Analyst Count
- JNPR 6
- EXEL 18
- Target Price
- JNPR $39.80
- EXEL $37.24
- AVG Volume (30 Days)
- JNPR 3.0M
- EXEL 2.9M
- Earning Date
- JNPR 04-24-2025
- EXEL 04-29-2025
- Dividend Yield
- JNPR 2.47%
- EXEL N/A
- EPS Growth
- JNPR N/A
- EXEL 170.77
- EPS
- JNPR 0.86
- EXEL 1.76
- Revenue
- JNPR $5,073,600,000.00
- EXEL $2,168,701,000.00
- Revenue This Year
- JNPR $9.41
- EXEL $5.45
- Revenue Next Year
- JNPR $3.95
- EXEL $10.32
- P/E Ratio
- JNPR $41.44
- EXEL $21.14
- Revenue Growth
- JNPR N/A
- EXEL 18.49
- 52 Week Low
- JNPR $33.72
- EXEL $20.14
- 52 Week High
- JNPR $39.79
- EXEL $40.02
- Technical
- Relative Strength Index (RSI)
- JNPR 38.56
- EXEL 52.55
- Support Level
- JNPR $35.37
- EXEL $37.26
- Resistance Level
- JNPR $36.19
- EXEL $40.02
- Average True Range (ATR)
- JNPR 0.38
- EXEL 1.16
- MACD
- JNPR 0.00
- EXEL 0.05
- Stochastic Oscillator
- JNPR 24.48
- EXEL 44.02
About JNPR Juniper Networks Inc.
Juniper Networks Inc is engaged in designing, developing, and selling products and services for high-performance networks to enable customers to build scalable, reliable, secure, and cost-effective networks for their businesses while achieving agility and improved operating efficiency through automation. The company's high-performance network and service offerings include routing, switching, Wi-Fi, network security, artificial intelligence (AI) or AI-enabled enterprise networking operations (AIOps), and software-defined networking (SDN) technologies. In addition to the company's products, the company offers its customers a variety of services, including maintenance and support, professional services, Software-as-a-Service ("SaaS"), and education and training programs.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.